A 35-year-old man who spent sixteen months shuttling between three different diagnoses and four failed therapies has emerged as a striking demonstration of what dual-targeted immunotherapy can achieve in psoriatic arthritis. Physicians treating him added the oral JAK inhibitor upadacitinib to his ongoing injections of ixekizumab, an IL-17 blocker, and within weeks his joint pain […]
A 35-year-old man who spent sixteen months shuttling between three different diagnoses and four failed therapies has emerged as a striking demonstration of what dual-targeted immunotherapy can achieve in...
Physicians treating him added the oral JAK inhibitor upadacitinib to his ongoing injections of ixekizumab, an IL-17 blocker, and within weeks his joint pain […]
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
A 35-year-old man who spent sixteen months shuttling between three different diagnoses and four failed therapies has emerged as a striking demonstration of what dual-targeted immunotherapy can achieve in psoriatic arthritis. Physicians treating him added the oral JAK inhibitor upadacitinib to his ongoing injections of ixekizumab, an IL-17 blocker, and within weeks his joint pain […]
Open the app view to save this story, compare related coverage, and continue from the same source.